News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Robert Z. Orlowski: Myeloma Paper of the Day
Photo taken from Robert Z. Orlowski/X
Feb 14, 2024, 13:50

Robert Z. Orlowski: Myeloma Paper of the Day

Robert Z. Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, posted on X/Twitter:

“Myeloma Paper of the Day: Matching-adjusted indirect comparison of efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma suggests that elranatamab may have better ORR and CR rates, and better PFS and OS.”

 

Image

View additional information.
Source: Robert Z. Orlowski/X

cancer elranatamab multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Robert Z. Orlowski teclistamab
Special Coverage
Blog
Mar 31, 2025, 06:10
The lung cancer patient advocacy sessions at the ELCC 2025 were standout events - Lung Cancer Europe
Insight
Mar 31, 2025, 06:04
Yan Leyfman: Expanding Antibody Therapeutics with TCR Mimicry 
Blog
Mar 31, 2025, 05:50
Jennifer Bires: Proud to speak on AI and mental health at NCCS Cancer Advocacy’s Spring 2025 Cancer Policy Roundtable
Insight
Mar 31, 2025, 05:03
Jarushka Naidoo: My ELCC 2025 Top 3 - MARIPOSA, KRYSTAL7 and Deescalation trials
Blog
Mar 31, 2025, 04:59
Michael Sapienza: Federal funding for cancer and other disease research has been cut by more than $1 billion
Blog
Mar 31, 2025, 04:45
Amil Družić: Excited to be part of the upcoming Young Cancer Professionals Roundtable
Blog
Mar 31, 2025, 03:27
Inside Cancer Careers Podcast Concluding – Thank You to our guests and listeners for two incredible years: Train at NCI
Blog
Mar 31, 2025, 02:59
Ariana Znaor: Consultation period for International Classification of Diseases for Oncology, 4th Edition is extended
Blog
Mar 31, 2025, 02:16
Peter Pisters: Delighted to serve as keynote speaker at Opportunity Austin's quarterly meeting
Blog
Mar 30, 2025, 23:21
Sachin H. Jain: How has "expert bias" mislead you in your work?
Blog
Mar 30, 2025, 22:48
HESI THRIVE 2025 Seed Grant Program - Funding Opportunity for Innovative Cancer Research
Insight
Mar 30, 2025, 21:29
Bishoy Morris Faltas: AI model that predicts response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer